Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready
Vir Biotechnology Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 6 pending office actions. These actions are spread across 6 distinct examiners, indicating a high level of individual examiner interaction for the company's legal team. The prosecution is further distributed across 4 distinct art units, which shows that the company's active applications cover a variety of specialized sub-fields within the broader biotechnology sector. This administrative spread requires the company to manage distinct timelines and examiner preferences simultaneously.
The busiest examiner for the portfolio is ALAM, DANYAL HASSAN, who is currently managing 1 busiest examiner pending office action. Because the number of pending actions is equal to the number of distinct examiners, the workload is distributed with no examiner handling multiple files. This lack of examiner concentration suggests that the company's current prosecution phase is administratively diverse. Practitioners must navigate the specific standards of the 4 distinct art units involved, as each unit has its own procedural expectations and technical focuses that impact the overall success of the portfolio.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (50%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| SCHWECHTER, BRANDON ROSS | 1 | 0.0% | +0.0% |
| MEYERING, SHABANA SHABBEER | 1 | 70.6% | +42.3% |
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
| ZOU, NIANXIANG | 1 | 64.1% | +24.8% |
| BUCKMASTER, MARLENE VRENI | 1 | 25.8% | +78.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17607383 | ANTIBODIES AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION | BUCKMASTER, MARLENE VRENI | 147d overdue |
| 18262872 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION | GODDARD, LAURA B | 21d |
| 18563674 | ENGINEERED POLYPEPTIDES | SCHWECHTER, BRANDON ROSS | — |
| 18559756 | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS | MEYERING, SHABANA SHABBEER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17607383 | ANTIBODIES AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION | BUCKMASTER, MARLENE VRENI | 147d overdue |
| 18262872 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION | GODDARD, LAURA B | 21d |
| 17611063 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | ZOU, NIANXIANG | 34d |
| 18559756 | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS | MEYERING, SHABANA SHABBEER | — |
| Art Unit | Apps |
|---|---|
| 1672 | 2 |
| 1635 | 1 |
| 1642 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686635 | METHODS FOR PRODUCING CMV VECTORS | ALAM, DANYAL HASSAN | 1672 | §103 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18563674 | ENGINEERED POLYPEPTIDES | SCHWECHTER, BRANDON ROSS | — | §102§112 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18559756 | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS | MEYERING, SHABANA SHABBEER | 1635 | §103§112 | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18262872 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION | GODDARD, LAURA B | 1642 | §102§103§112Other | Non-Final OA | 21d | Pending | Jul 25, 2023 |
| 17611063 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | ZOU, NIANXIANG | 1671 | §103 | Non-Final OA | 34d | Pending | Nov 12, 2021 |
| 17607383 | ANTIBODIES AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION | BUCKMASTER, MARLENE VRENI | 1672 | §103Other | Final Rejection | 147d overdue | Pending | Oct 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial